2016年

1.楊剛毅作為通訊作者在Sci Rep 6發(fā)表論文Circulating Zinc-alpha2-glycoprotein levels and Insulin Resistance in Polycystic Ovary Syndrome tein levels and Insulin Resistance in Polycystic Ovary Syndrome，影響因子5.578。

2.楊剛毅作為通訊作者在Sci Rep 6發(fā)表論文NAMPT knockdown attenuates atherosclerosis and promotes reverse cholesterol transport in ApoE KO mice with high-fat-induced insulin resistance，影響因子5.578。

3.楊剛毅作為通訊作者在J Hypertens.發(fā)表論文Effect of renal sympathetic denervation on hepatic glucose metabolism and blood pressure in a rat model of insulin resistance.影響因子5.062。

4.李鈳作為共同第一作者在Int J Obes (Lond). 發(fā)表論Central administration of vaspin inhibits glucose production and augments hepatic insulin signaling in high-fat-diet-fed rat. 影響因子5.377。

2017年

5.楊剛毅作為通訊作者在Cell Death Dis 8: e2609.發(fā)表論文Duodenal GLP-1 signaling regulates hepatic glucose production through a PKC-delta-dependent neurocircuitry.，影響因子5.378。

6.龍敏作為第一作者在Nutr Diabetes 7: e281.發(fā)表論文Glycated hemoglobin A1C and vitamin D and their association with diabetic retinopathy severity. ，影響因子2.773。

7.楊剛毅作為通訊作者在Oncotarget 8:100603-100613發(fā)表論文Potassium measurements and risk of type 2diabetes:a dose-response meta-analysis of prospective cohort studies .影響因子5.008。

2018年

8.楊剛毅作為通訊作者在J Clin Endocrinol Metab 103: 139-147.發(fā)表論文Myonectin Predicts the Development of Type 2 Diabetes. 影響因子5.455。

9.楊剛毅作為通訊作者在J Endocrinol Invest.發(fā)表論文The association between circulating irisin levels and different phenotypes of polycystic ovary syndrome.  影響因子2.633。

10.楊剛毅作為通訊作者在Acta Diabetol.發(fā)表論文C1q/TNF-related protein-6 is associated with insulin resistance and the development of diabetes in Chinese population.  影響因子3.34。

11.楊剛毅作為通訊作者在Cell Physiol Biochem. 發(fā)表論文High Circulating Alarin Levels Are Associated with Presence of Metabolic Syndrome影響因子5.104。

12.楊剛毅作為通訊作者在Cell Death Dis. 發(fā)表論文JAZF1 ameliorates age and diet-associated hepatic steatosis through SREBP-1c -dependent mechanism影響因子5.64。

13.李生兵作為第一作者，張利莉作為通訊作者在Diabetes Research

and Clinical Practice發(fā)表論文 Efficacy of low-level light therapy for treatment of diabetic foot ulcer: A systematic review and metaanalysis of randomized controlled trials影響因子3.369。

2019年

14.袁磊作為共同第一作者，劉東方作為通訊作者在Clinical Endocrinology 發(fā)表論文Changes in whole metabolites after exenatide treatment in overweight/obese polycystic ovary syndrome patients.影響因子2.897。

15.楊剛毅作為通訊作者在Cell Commun Signal 發(fā)表論文Gut ghrelin regulates hepatic glucose production and insulin signaling via a gut-brain-liver pathway.影響因子3.943。

16.楊剛毅作為通訊作者在Nanoscale 發(fā)表論文 Effective gene delivery of shBMP-9 using polyethyleneimine-based core-shell nanoparticles in an animal model of insulin resistance. 影響因子7.367。

17.王蔥作為第一作者，張利莉作為通訊作者在Cytokine.發(fā)表論文 Increased plasma osteopontin levels are associated with nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.影響因子3.078。

18.楊剛毅作為通訊作者在J Mol Cell Biol.發(fā)表論文 CILP-2 is a novel secreted protein and associated with insulin resistance. 影響因子5.595。

19.李生兵作為第一作者，劉東方作為通訊作者在Blood Pressure Monitoring發(fā)表論文The characteristics of 24-hour ambulatory blood pressure monitoring and its relationship with cardiovascular target organ damage in Chinese Han patients with concomitant type  2 diabetes and hypertension 影響因子1.2。

20.劉東方作為通訊作者在Metabolic Syndrome and Related Disorders發(fā)表論文Screening for a Simple and Effective Indicator of Insulin Resistance in Chinese Reproductive-Aged Women, with the Insulin Clamp Technique as a Reference. 影響因子1.597。

21.段雅倩作為第一作者在circulation research發(fā)表論文Bone Marrow-Derived Cells Restore Functional Integrity of the Gut Epithelial and Vascular Barriers in a Model of Diabetes and ACE2 Deficiency.影響因子15.86。

22.楊剛毅作為通訊作者在Diabetes發(fā)表論文 Osteoprotegerin Promotes Liver Steatosis by Targeting the ERK-PPARγ-CD36 Pathway影響因子8.01。

2020年

23.楊剛毅作為通訊作者在JOURNAL OF DIABETES RESEARCH 發(fā)表論文 TERT and Akt Are Involved in the Par-4-Dependent Apoptosis of Islet beta Cells in Type 2 Diabetes 影響因子3.04。

24.賴業(yè)瑞作為第一作者，楊剛毅作為通訊作者在EMBO REPORTS發(fā)表論文 DOCK5 regulates energy balance and hepatic insulin sensitivity by targeting mTORC1 signaling影響因子8.383。

25.魏潔作為第一作者，劉東方作為通訊作者在HORMONE AND METABOLICRESEARCH發(fā)表論文Decreased Circulating MANF in Women with PCOS is Elevated by Metformin Therapy and is Inversely Correlated with Insulin Resistance and Hyperandrogenism影響因子2.423。

26.羅夑作為第一作者，劉東方作為通訊作者在Life Sciences發(fā)表論文Liraglutide protects pancreatic beta cells from endoplasmic reticulum stress by upregulating MANF to promote autophagy turnover影響因子3.647。

27.王蔥作為第一作者，張利莉作為通訊作者在World J Gastroenterol發(fā)表論文Mesencephalic astrocyte-derived neurotrophic factor ameliorates steatosis in HepG2 cells by regulating hepatic lipid metabolism影響因子3.665。

28.楊剛毅作為通訊作者在BMC ENDOCRINE DISORDER 發(fā)表論文Serum Fetuin-A levels are increased and associated with insulin resistance in women with polycystic ovary syndrome影響因子1.994。

29.田茗源作為第一作者，劉東方作為通訊作者在ACS OMEGA發(fā)表論文Protein Expression Profile in IVF Follicular Fluid and Pregnancy Outcome Analysis in Euthyroid Women with Thyroid Autoimmunity影響因子2.870。

30.劉東方作為通訊作者在ENDOCRINE  發(fā)表論文Thioredoxin-interacting protein: a critical link between autophagy disorders and pancreatic beta-cell dysfunction影響因子3.235。

31.楊剛毅作為通訊作者在DIABETES-METABOLISM RESEARCH AND REVIEWS 發(fā)表論文Association between circulating follistatin-like-1 and metabolic syndrome in middle-aged and old population: A cross-sectional study影響因子3.314。

32.李鈳作為共同第一作者，楊剛毅作為通訊作者在Oxidative Medicine and Cellular Longevity發(fā)表論文Circulating Levels of CILP2 Are Elevated in Coronary Heart Disease and Associated with Atherosclerosis影響因子5.027。

內(nèi)分泌代謝病科截止目前承擔(dān)過國家自然基金20余項，省部級課題10余項，團(tuán)隊課題經(jīng)費累計達(dá)600余萬，目前在研項目12項，在研國家自然基金8項，在研省部級課題4項，經(jīng)費達(dá)300余萬。

在Diabetes、Diabetes Care、Circulation Reseach,JCEM等國內(nèi)外重要雜志發(fā)表論文200余篇，SCI影響因子超過300余分，平均影響因子為4.3 分，最高單篇影響因子為15.86分。參編教材1部，參與制定專業(yè)指南及共識2部，團(tuán)隊近年獲中華醫(yī)學(xué)科技三等獎、重慶市醫(yī)學(xué)科技成果一等獎、重慶市科技進(jìn)步獎三等獎等3項，多次在ADA、EASD等重要國際會議進(jìn)行大會發(fā)言，科研工作在國際國內(nèi)具有較強(qiáng)影響力。

相關(guān)知識

肥胖癥的健康指導(dǎo) 內(nèi)分泌代謝科
內(nèi)分泌
內(nèi)分泌內(nèi)科（減重/糖尿病共同照護(hù)） 特色醫(yī)療
【內(nèi)分泌失調(diào)】什么是內(nèi)分泌失調(diào)
【內(nèi)分泌失調(diào)】內(nèi)分泌失調(diào)怎么調(diào)理
調(diào)理內(nèi)分泌
中醫(yī)內(nèi)科是內(nèi)分泌科嗎
脊柱與肥胖、內(nèi)分泌、代謝、情緒——認(rèn)識一下我們自己的脊柱（四）
內(nèi)分泌失調(diào)為何成為流行病
女性調(diào)理內(nèi)分泌的方法內(nèi)分泌

網(wǎng)址: 內(nèi)分泌代謝病科 http://m.u1s5d6.cn/newsview660063.html